TrialDiabetes, obesity & metabolism2020

Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.

Stefano Del Prato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.